- Home
- AMRN vs NMRA Comparison
AMRN vs NMRA Comparison
Compare AMRN & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMRN
- NMRA
- Stock Information
- Founded
- AMRN 1989
- NMRA 2019
- Country
- AMRN Ireland
- NMRA United States
- Employees
- AMRN N/A
- NMRA N/A
- Industry
- AMRN Biotechnology: Pharmaceutical Preparations
- NMRA
- Sector
- AMRN Health Care
- NMRA
- Exchange
- AMRN Nasdaq
- NMRA Nasdaq
- Market Cap
- AMRN 317.1M
- NMRA 268.5M
- IPO Year
- AMRN 1993
- NMRA 2023
- Fundamental
- Price
- AMRN $15.01
- NMRA $1.62
- Analyst Decision
- AMRN Strong Sell
- NMRA Buy
- Analyst Count
- AMRN 1
- NMRA 8
- Target Price
- AMRN $12.00
- NMRA $7.14
- AVG Volume (30 Days)
- AMRN 55.2K
- NMRA 383.3K
- Earning Date
- AMRN 10-29-2025
- NMRA 11-11-2025
- Dividend Yield
- AMRN N/A
- NMRA N/A
- EPS Growth
- AMRN N/A
- NMRA N/A
- EPS
- AMRN N/A
- NMRA N/A
- Revenue
- AMRN $219,361,000.00
- NMRA N/A
- Revenue This Year
- AMRN N/A
- NMRA N/A
- Revenue Next Year
- AMRN N/A
- NMRA N/A
- P/E Ratio
- AMRN N/A
- NMRA N/A
- Revenue Growth
- AMRN N/A
- NMRA N/A
- 52 Week Low
- AMRN $7.08
- NMRA $0.61
- 52 Week High
- AMRN $17.49
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- AMRN 46.36
- NMRA 47.71
- Support Level
- AMRN $14.80
- NMRA $1.60
- Resistance Level
- AMRN $15.46
- NMRA $1.70
- Average True Range (ATR)
- AMRN 0.50
- NMRA 0.09
- MACD
- AMRN -0.05
- NMRA -0.01
- Stochastic Oscillator
- AMRN 27.74
- NMRA 8.51
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.